S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
NASDAQ:AUPH

Aurinia Pharmaceuticals (AUPH) Price Target & Analyst Ratings

$9.54
+0.42 (+4.61%)
(As of 06/2/2023 ET)
Compare
Today's Range
$9.11
$9.54
50-Day Range
$8.96
$11.69
52-Week Range
$4.07
$13.41
Volume
1.90 million shs
Average Volume
2.45 million shs
Market Capitalization
$1.36 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.00

Aurinia Pharmaceuticals Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 4 Analyst Ratings

Consensus Analyst Price Target

$13.00
36.27% Upside
High Prediction$14.00
Average Prediction$13.00
Low Prediction$12.00
TypeCurrent
6/4/22 to 6/4/23
1 Month Ago
5/5/22 to 5/5/23
3 Months Ago
3/6/22 to 3/6/23
1 Year Ago
6/4/21 to 6/4/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
4 Buy rating(s)
6 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$13.00$13.00$12.50$25.60
Predicted Upside36.27% Upside78.47% Upside95.09% Upside68.79% Upside
Get Aurinia Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter.


AUPH Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AUPH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Aurinia Pharmaceuticals Stock vs. The Competition

TypeAurinia PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.75
2.66
2.49
Consensus RatingModerate BuyBuyHold
Predicted Upside36.27% Upside1,263.19% Upside209.77% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/2/2023Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$11.00 ➝ $13.00+18.40%
11/7/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$26.00 ➝ $14.00+171.84%
11/4/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$17.00 ➝ $12.00+131.66%
11/4/2022Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
(Data available from 6/4/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












AUPH Price Target - Frequently Asked Questions

What is Aurinia Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 4 analysts in the last year, the consensus rating for Aurinia Pharmaceuticals stock is Moderate Buy based on the current 1 hold rating and 3 buy ratings for AUPH. The average twelve-month price prediction for Aurinia Pharmaceuticals is $13.00 with a high price target of $14.00 and a low price target of $12.00. Learn more on AUPH's analyst rating history.

Do Wall Street analysts like Aurinia Pharmaceuticals more than its competitors?

Analysts like Aurinia Pharmaceuticals more than other Medical companies. The consensus rating for Aurinia Pharmaceuticals is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how AUPH compares to other companies.

Does Aurinia Pharmaceuticals's stock price have much upside?

According to analysts, Aurinia Pharmaceuticals's stock has a predicted upside of 78.47% based on their 12-month price targets.

What analysts cover Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals has been rated by Royal Bank of Canada in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:AUPH) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -